Ambrx partners with Zhejiang for breast cancer antibody drug conjugate development

Ambrx has partnered with Zhejiang Medicine for the development and commercialization of ARX788, its antibody drug conjugate (ADC) for breast cancer... Targeting Her2-positive breast cancer, ARX788 is developed by the clinical stage biopharmaceutical company Ambrx as site-specific ADC.

http://contractresearch.pharmaceutical-business-review.com/news/ambrx-partners-with-zhejiang-for-breast-cancer-antibody-drug-conjugate-development-170613